Stocks of the Hour: Immutep, Lepidico, Mithril Silver and Gold
Immutep (ASX:IMM) has reported that eftilagimod alpha (efti) combined with MSD’s KEYTRUDA® shows high efficacy and a favourable safety profile for treating head and neck cancer. The TACTI-003 trial revealed a 31.0% overall response rate in patients with high PD-L1 expression, highlighting efti’s potential to improve treatment outcomes without added toxicity. Shares are trading 12.5 […]
Stocks of the Hour: Immutep, Lepidico, Mithril Silver and Gold Read More »